Shares of Healthcare sector company Unicycive Therapeutics moved -31.4% today, and are now trading at a price of $0.46. The small-cap stock's daily volume was 8,341,967 compared to its average volume of 34,008. The S&P 500 index returned a -0.8% performance.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company is based in Los Altos and has 9 full time employees. Its market capitalization is $6,933,258.
4 analysts are following Unicycive Therapeutics and have set target prices ranging from $3 to $13.5 per share. On average, they have given the company a rating of buy. At today's prices, UNCY is trading -95.1% away from its average analyst target price of $9.38 per share.
Over the last year, UNCY shares have gone down by -66.0%, which represents a difference of -45.9% when compared to the S&P 500. The stock's 52 week high is $2.35 per share and its 52 week low is $0.4. Unicycive Therapeutics has averaged free cash flows of $-2,810,333.3 over the last four years, with a mean growth rate of -160.7%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ MM) | Capital expenditures ($ MM) | Free Cash Flow ($ MM) | YoY Growth (%) |
|---|---|---|---|---|
| 2021-12-31 | -6 | -0 | -6 | -297.26 |
| 2020-12-31 | -1 | 0 | -1 | -24.06 |
| 2019-12-31 | -1 | 0 | -1 | n/a |
